AVR.ASX: SEC Form S-1 Registration Statement

SEC Form S-1 Registration Statement

Stock	Anteris Technologies Ltd (AVR.ASX)
Release Time	27 Nov 2025, 9:09 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Anteris Files SEC Form S-1 Registration Statement

Key Points

Anteris filed Form S-1 with SEC to register securities issued under private placement
Registration allows resale of securities by selling stockholders
Anteris is a global structural heart company developing cutting-edge medical devices

Full Summary

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, filed the attached Form S-1 with the U.S. Securities and Exchange Commission on 26 November 2025 US Central time (27 November 2025 AEST). The Form S-1 relates to registration of the securities issued under the private placement as announced to ASX on 28 October 2025 to permit resale of those securities by the selling stockholders in accordance with the U.S. Securities Act of 1933. Anteris is a science-driven company with an experienced team delivering restorative solutions to structural heart disease patients. The company's lead product, the DurAVR® Transcatheter Heart Valve, is designed to treat aortic stenosis and aims to replicate normal aortic blood flow.